Yahoo · Nov 16, 2026
Why Didn't Tilray Brands Make a Bid for Aurora Cannabis?
Multiple companies have made offers for Aurora's business this year, but Tilray hasn't shown any interest.

NASDAQ · OGI
Healthcare · Drug Manufacturers - Specialty & Generic
$0.58
Down-$0.05 (-7.40%)
Updated Nov 21, 2026, 8:35 PM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · OGI
1M range · 21 trading sessions · Daily adjusted prices
Prices through Nov 20, 2026
OGI closed at $0.58 after 21 trading sessions, down 37.05% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 20, 2026 | $0.6225 | $0.6486 | $0.583 | $0.583 | 1M |
| Nov 19, 2026 | $0.661 | $0.6765 | $0.6253 | $0.6296 | 1.39M |
| Nov 18, 2026 | $0.701 | $0.7293 | $0.67 | $0.6766 | 649.32K |
| Nov 17, 2026 | $0.732 | $0.7443 | $0.691 | $0.7069 | 1.03M |
| Nov 16, 2026 | $0.811 | $0.812 | $0.7101 | $0.724 | 1.16M |
| Nov 13, 2026 | $0.84 | $0.84 | $0.80 | $0.8286 | 408.85K |
| Nov 12, 2026 | $0.85 | $0.8583 | $0.8231 | $0.834 | 573.33K |
| Nov 11, 2026 | $0.85 | $0.8787 | $0.8414 | $0.8537 | 580.94K |
| Nov 10, 2026 | $0.87 | $0.8887 | $0.8501 | $0.8524 | 459.13K |
| Nov 9, 2026 | $0.885 | $0.8998 | $0.8707 | $0.876 | 709.06K |
| Nov 6, 2026 | $0.9328 | $0.9414 | $0.8731 | $0.8766 | 1.13M |
| Nov 5, 2026 | $0.98 | $0.98 | $0.89 | $0.9298 | 1.66M |
| Nov 4, 2026 | $0.9401 | $0.9671 | $0.9151 | $0.965 | 1.99M |
| Nov 3, 2026 | $0.93 | $0.9748 | $0.8606 | $0.9199 | 1.73M |
| Nov 2, 2026 | $0.94 | $0.9784 | $0.9326 | $0.9651 | 186.34K |
| Oct 30, 2026 | $0.951 | $0.9699 | $0.93 | $0.9331 | 205.06K |
| Oct 29, 2026 | $0.9502 | $0.9775 | $0.936 | $0.9605 | 207.52K |
| Oct 28, 2026 | $0.93 | $0.9599 | $0.93 | $0.9553 | 99.06K |
| Oct 27, 2026 | $0.93 | $0.9493 | $0.93 | $0.9392 | 168.38K |
| Oct 26, 2026 | $0.92 | $0.94 | $0.9101 | $0.939 | 432.62K |
| Oct 23, 2026 | $0.9299 | $0.9529 | $0.921 | $0.9262 | 189.29K |
The latest Smart Investors Daily articles mentioning OGI.
Company
Market Activity
Research & News
OGI research
Company profile and research snapshot.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 20, 2026 | CANACCORD GENUITY | Buy | — |
| Aug 12, 2026 | ATB CAPITAL MARKETS | Outperform | — |
| Aug 11, 2026 | ALLIANCE GLOBAL PARTNERS | Buy | — |
| Aug 11, 2026 | HAYWOOD SECURITIES INC. | Buy | — |
| May 13, 2026 | ATB CAPITAL MARKETS | Outperform | — |
No generated briefing is available yet.
Yahoo · Nov 16, 2026
Multiple companies have made offers for Aurora's business this year, but Tilray hasn't shown any interest.
Yahoo · Nov 16, 2026
Omeros (OMER) delivered earnings and revenue surprises of +220.00% and +16.29%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Nov 13, 2026
TORONTO, November 13, 2026--Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI) (the "Company" or "Organigram"), Canada's #1 cannabis company by market share¹ and a growing global cannabis platform, today announced that on November 11, 2026, it received notification (the "Notification") from The Nasdaq Stock Market LLC ("Nasdaq") that it is not in compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Select Market. The Notif
Yahoo · Nov 10, 2026
Organigram CEO James Yamanaka says in an exclusive interview that Aurora’s European medical business will drive growth, even as Curaleaf argues the C$7.80 deal is a bad one for Organigram shareholders.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning OGI.